MSLN and cancer: Moreover, we also observed a clonal non-synonymous mutation in MSLN, a plasma membrane differentiation antigen which is emerging as an attractive target for cancer immunotherapy due to its potential involvement in the epithelial-to-mesenchymal transition, a cellular process thought to be required for metastatic dissemination12.